Authors
Chee Khoon Lee, Johnathan Man, Sally Lord, Wendy Cooper, Matthew Links, Val Gebski, Roy S Herbst, Richard J Gralla, Tony Mok, James Chih-Hsin Yang
Publication date
2018/2/1
Source
JAMA oncology
Volume
4
Issue
2
Pages
210-216
Publisher
American Medical Association
Description
Importance
Checkpoint inhibitors have replaced docetaxel as the new standard second-line therapy in advanced non–small cell lung carcinoma (NSCLC), but little is known about the potential predictive value of clinical and molecular characteristics.
Objective
To estimate the relative efficacy of checkpoint inhibitor vs docetaxel overall and in subgroups defined by clinicopathological characteristics.
Data Sources
This systematic review and meta-analysis searched MEDLINE, Embase, PubMed, and the Cochrane Central Register of Controlled Trials for randomized clinical trials published in the English language between January 1, 1996, and January 30, 2017.
Study Selection
Randomized clinical trials that compared a checkpoint inhibitor (nivolumab, pembrolizumab, or atezolizumab) with docetaxel. For each trial included in this study, the trial name, year of publication or conference presentation, patients …
Scholar articles
CK Lee, J Man, S Lord, W Cooper, M Links, V Gebski… - JAMA oncology, 2018